Mesoblast limited (OTCMKTS:MEOBF) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.07 and traded as high as $1.21. Mesoblast shares last traded at $1.21, with a volume of 5,000 shares trading hands.
The company has a 50 day simple moving average of $1.21 and a 200-day simple moving average of $1.07.
Mesoblast Company Profile (OTCMKTS:MEOBF)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.